The Influence of Fluticasone Inhalation on Intermediate Markers of Carcinogenesis in the Bronchial Epithelium of a High Risk Population : A Double Blind Placebo-Controlled Randomised Phase II Study
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 90
- 试验地点
- 2
- 主要终点
- Reversal of histological abnormality bronchial biopsies at 6 months
研究概览
简要总结
The purpose of this study is to assess the efficacy of fluticasone on the development of lung cancer in smokers
详细描述
Bronchial epithelium exposed to cigarette smoke undergoes a series of histological changes that may ultimately lead to invasive cancer. In rats exposed to cigarette smoke inhaled corticosteroids reduce the number of lung tumors. The purpose of this study is to assess the efficacy of fluticasone on premalignant lesions in volunteers with a smoking history of >10 pack-years and patients cured of head and neck cancer or lung cancer. Participants are screened for premalignant lesions by bronchoscopy and if these are present randomised to receive a powder inhalation device containing either fluticasone 500 μg or a placebo. After 6 months, biopsies are taken from the same locations. Efficacy of treatment is assessed by reversal of metaplasia/dysplasia; secondary end-points are reversal of increased p53 immunoreactivity and hTERT expression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •signed informed consent
- •age over 18
- •metaplasia index > 15%
- •over 25 pack years smoking history or history of lung- or head&neck cancer
- •male/female of non-childbearing potential or using approved contraception
排除标准
- •use of inhaled/systemic corticosteroid drugs in the preceding 12 months
- •contraindications for bronchoscopy/use of fluticasone
- •major illness
- •Baseline FEV1<1000ml
- •Previous participation in clinical study
- •nodules > 1cm on CT
结局指标
主要结局
Reversal of histological abnormality bronchial biopsies at 6 months
次要结局
- Reversal of suprabasal p53 staining at 6 months
- Reversal of elevated hTERT mRNA levels at 6 months
- Reversal of increased KI-67 at 6 months
